Abstract
Cardiovascular diseases, including myocardial infarction and heart failure, are the main causes of death worldwide. Classical pharmacological treatment may halt, but cannot reverse the underlying disease process. Cellular cardiomyoplasty has the potential to reconstruct myocardium in situ; yet, it is hampered by poor cell survival, engraftment, and differentiation. Tissue engineering has emerged as an alternative cell-based approach, aiming at partial or full replacement of damaged organs with in vitro generated tissue equivalents. However, limited availability of therapeutic cardiomyocytes poses a major challenge on cell-based and in particular tissue engineering-based therapies. Rapidly evolving stem cell technologies, enabling mass cultures may overcome this limitation. Translating available experimental concepts into clinical reality will be the ultimate challenge. This review discusses potentially therapeutic cells for cardiac repair, current stem cell-based myocardial tissue engineering strategies, and the requirements for a translation of myocardial tissue engineering into clinical practice.
Keywords: Myocardial infarction, heart failure, cardiomyoplasty, tissue engineering, myocardial regeneration, stem cells
Current Pharmaceutical Biotechnology
Title:Myocardial Tissue Engineering and Heart Muscle Repair
Volume: 14 Issue: 1
Author(s): Bijoy Chandapillai Karikkineth and Wolfram-Hubertus Zimmermann
Affiliation:
Keywords: Myocardial infarction, heart failure, cardiomyoplasty, tissue engineering, myocardial regeneration, stem cells
Abstract: Cardiovascular diseases, including myocardial infarction and heart failure, are the main causes of death worldwide. Classical pharmacological treatment may halt, but cannot reverse the underlying disease process. Cellular cardiomyoplasty has the potential to reconstruct myocardium in situ; yet, it is hampered by poor cell survival, engraftment, and differentiation. Tissue engineering has emerged as an alternative cell-based approach, aiming at partial or full replacement of damaged organs with in vitro generated tissue equivalents. However, limited availability of therapeutic cardiomyocytes poses a major challenge on cell-based and in particular tissue engineering-based therapies. Rapidly evolving stem cell technologies, enabling mass cultures may overcome this limitation. Translating available experimental concepts into clinical reality will be the ultimate challenge. This review discusses potentially therapeutic cells for cardiac repair, current stem cell-based myocardial tissue engineering strategies, and the requirements for a translation of myocardial tissue engineering into clinical practice.
Export Options
About this article
Cite this article as:
Chandapillai Karikkineth Bijoy and Zimmermann Wolfram-Hubertus, Myocardial Tissue Engineering and Heart Muscle Repair, Current Pharmaceutical Biotechnology 2013; 14 (1) . https://dx.doi.org/10.2174/1389201011314010003
DOI https://dx.doi.org/10.2174/1389201011314010003 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Leukocyte Influx in Atherosclerosis
Current Drug Targets Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
Current Topics in Medicinal Chemistry Leucine-zipper and Sterile-α Motif Kinase (ZAK): A Potential Target for Drug Discovery
Current Medicinal Chemistry Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design Vitamin D Analogs as Anti-Carcinogenic Agents
Anti-Cancer Agents in Medicinal Chemistry Subject Index To Volume 4
Current Vascular Pharmacology An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy
Medicinal Chemistry Biomarkers for Risk Assessment and Prevention of Breast Cancer
Current Cancer Drug Targets The Urokinase Receptor Interactome
Current Pharmaceutical Design Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Current Vascular Pharmacology The Predictive Role for ST2 in Patients with Acute Coronary Syndromes and Heart Failure
Current Medicinal Chemistry Infants and Children with Tachycardia: Natural History and Drug Administration
Current Pharmaceutical Design Obstructive Sleep Apnea Syndrome: Implications in Cardiovascular Disease
Current Respiratory Medicine Reviews Drug Therapy Aimed at Adenylyl Cyclase to Regulate Cyclic Nucleotide Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets Evidence for Pleiotropic Effects of Statins in Clinical Trials
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Myocardial Revascularization for the Elderly: Current Options, Role of Off-pump Coronary Artery Bypass Grafting and Outcomes
Current Cardiology Reviews Crystal Structures of Phosphodiesterases and Implications on Substrate Specificity and Inhibitor Selectivity
Current Topics in Medicinal Chemistry Working Towards the Development of Vaccines for the Treatment and Prevention of Early Breast Cancer
Current Cancer Therapy Reviews Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Mitochondrial Dysfunction and Alzheimers Disease
Current Alzheimer Research